Nucleotide analogs

Patent metadata

Field	Value
Publication number	US-10213430-B2
Application number	US-201715718898-A
Country	US
Kind code	B2
Filing date	Sep 28, 2017
Priority date	Sep 15, 2014
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

First claim

What is claimed is:

1. A compound of Formula (I)

or a pharmaceutically acceptable salt thereof;
wherein
B 1 is

Z 1 and Z 2 are oxygen;
R 1 is —(CHR 4 ) a —O—C 1-24 alkyl;
R 2 is aryl(C 1-4 alkyl)—;
R 3 is selected from C 1-6 alkyl and C 3-6 cycloalkyl;
R 4 is hydrogen; and
a is selected from 1, 2, 3, or 4.

2. The compound of claim 1 , wherein R 3 is methyl.

3. The compound of claim 1 , wherein R 1 is —(CHR 4 ) a —O—C 1-24 alkyl; R 4 is hydrogen; and a is 2.

4. The compound of claim 1 , wherein R 2 is benzyl.

5. The compound of claim 1 , wherein
R 1 is —(CHR 4 ) a —O—C 1-24 alkyl; R 4 is hydrogen; and a is 2 or 3.

6. The compound of claim 5 , wherein R 1 is —(CH 2 ) 2 O—(CH 2 ) 17 CH 3 .

7. The compound of claim 6 , wherein R 2 is benzyl.

8. The compound of claim 5 , wherein R 1 is —(CH 2 ) 3 O—(CH 2 ) 15 CH 3 .

9. The compound of claim 8 , wherein R 2 is benzyl.

10. A pharmaceutical composition, comprising a compound of claim 1 , optionally in a pharmaceutically acceptable carrier.

11. A pharmaceutical composition, comprising a compound of claim 2 , optionally in a pharmaceutically acceptable carrier.

12. A pharmaceutical composition, comprising a compound of claim 3 , optionally in a pharmaceutically acceptable carrier.

13. A pharmaceutical composition, comprising a compound of claim 5 , optionally in a pharmaceutically acceptable carrier.

14. A pharmaceutical composition, comprising a compound of claim 6 , optionally in a pharmaceutically acceptable carrier.

15. A pharmaceutical composition, comprising a compound of claim 8 , optionally in a pharmaceutically acceptable carrier.

16. A compound of the structure:

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition, comprising a compound of claim 16 , optionally in a pharmaceutically acceptable carrier.

Assignees

• Univ California

Inventors

• Hostetler Karl Y
• Beadle James R
• Valiaeva Nadejda

Classifications

• C07F9/6574

  Esters of oxyacids of phosphorus {(C07F9/657163 takes precedence)} · CPC title

• C07F9/6571

  having phosphorus and oxygen atoms as the only ring hetero atoms · CPC title

• C07F9/6561

  containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title

• C07F9/40 Primary

  Esters thereof · CPC title

• A61P35/00

  Antineoplastic agents · CPC title